ARTICLE | Deals
Investors look behind the curtain of pharma-biotech deals
Having a big-name deal is no longer the validating event for a young biotech that it once was
April 21, 2022 9:02 PM UTC
Research collaborations, co-development agreements and licensing deals with pharmas are rarely the validating events for young biotechs that they once were. Now, it’s specific strategic and financial benefits in the deal terms, not simply pharma endorsement, that investors want to see.
New trends in deal flow, deal terms and market conditions have triggered a series of shifts in deal drivers for young biotechs over the last 20 years, and in the way investors factor deals into a biotech’s valuation. ...